Abstract 364P
Background
Lung cancer treatment gets on the stage of precision medicine. Histopathological classification of lung cancer is crucial in determining optimum treatment. Artificial intelligence (AI) models have been widely shown to be useful in pathological diagnosis and we previously established a reliable AI model to detect the presence of lung cancer on whole slide images (WSIs). However, AI models for the differentiation of major histological types of lung cancer, such as adenocarcinoma (ADC), squamous cell carcinoma (SCC) and small-cell lung cancer (SCLC), are yet to be established.
Methods
We trained a convolution neural network (CNN) based on the EfficientNet-B1 architecture to classify ADC, SCC, SCLC, and non-neoplastic lesion from biopsy specimen WSIs (70, 23, 12 and 171 specimens with ADC, SCC, SCLC and non-neoplastic lesion, respectively) using a training dataset of 276 images of which 60 were reserved for validation. The WSIs were manually annotated by pathologists by drawing around the regions that contain each subtype. We used a transfer learning approach, in which the starting weights were obtained from a pre-trained model on ImageNet. The model was then trained on our dataset using a supervised learning approach. To classify a WSI, the model was applied in a sliding window fashion with an input tile size of 224x224 and a stride of 128 on a magnification of x10. The maximum probability was then used as a WSI diagnosis.
Results
We evaluated our model on a total of 533 WSIs that only had WSI diagnoses. The model achieved a Receiver Operator Curve Area Under the Curves of 0.888 (CI 0.872-0.9075), 0.8913 (CI 0.8596-0.9221), 0.9526 (CI 0.9276-0.9646) for ADC, SCC, and SCLC, respectively.
Conclusions
The obtained results on a large test set are a promising first step towards developing a model for the classification of lung cancer. Our model was only trained on a small dataset of 276 WSIs; however, we hope that the model would be further improved with the collection of additional annotated WSIs for training. Having a high performing model could help reduce the burden on pathologists and be useful for the decision of optimum treatment strategies, such as molecular-targeted therapy, immunotherapy and chemotherapy, according to the histological types of lung cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
193P - First-line liposomal irinotecan + 5 fluorouracil/leucovorin + oxaliplatin in patients with pancreatic ductal adenocarcinoma: Exploratory survival analyses by change in post treatment CA 19-9
Presenter: Andrew Dean
Session: e-Poster Display Session
194P - Nab-paclitaxel plus capecitabine as first-line treatment for patients with recurrence or metastatic biliary tract cancer
Presenter: Jun Zhou
Session: e-Poster Display Session
370P - Bespoke circulating tumour DNA assay for the detection of minimal residual disease in esophageal adenocarcinoma patients
Presenter: Emma Ococks
Session: e-Poster Display Session
390P - A real-world clinical study of camrelizumab in the treatment of esophageal cancer
Presenter: Guoping Sun
Session: e-Poster Display Session
203P - Characterization of renal cell carcinoma (RCC) with VHL mutation
Presenter: Yanrui Zhang
Session: e-Poster Display Session
204P - Prospective observational study on pazopanib in patients treated for advanced or metastatic renal cell carcinoma (RCC) in Asia, North Africa and Middle East countries: Final analysis of PARACHUTE study
Presenter: Ravindran Kanesvaran
Session: e-Poster Display Session
205P - A study on organ preservation in muscle invasive urinary bladder cancer patients with intensity modulated radiotherapy and concurrent single agent cisplatin in south Indian population
Presenter: Himani Manchala
Session: e-Poster Display Session
206P - Mutational signature in urothelial carcinoma with TP53 mutation
Presenter: Huan Liu
Session: e-Poster Display Session
207P - Concordance of genomic alterations by next-generation sequencing in tumour tissue versus circulating tumour DNA in urothelial carcinoma
Presenter: wang Wang
Session: e-Poster Display Session
208P - Prognostic factors and outcomes of non-seminomatous germ cell tumours of testis: Experience from a tertiary cancer centre in India
Presenter: Lekha Nair
Session: e-Poster Display Session